GA
Gaudium IVF and Women Health Ltd (GAUDIUMIVF)
₹99.57
Mkt cap
₹773 Cr
P/E ratio
33.30
P/B
4.45
Div yield
0.00%
ROE
24.60%
ROCE
29.50%
EPS (TTM)
₹2.99
Book value
₹22
52W range
69–163
Sector
Healthcare
Price history
Previous close
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India. [1]
NSE GAUDIUMIVFBSE 544709
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−38.98% from high₹100
₹69+43.93% from low₹163
Current
₹99.57
Prev close
₹99.44
Day
+0.13%
Price performance
1D
+0.31%
1W
−6.02%
1M
+6.31%
3M
−12.25%
6M
−14.55%
1Y
—
YTD
+24.06%
Financials
Revenue, profit & margin
P/E ratio
33.3×
GAUDIUMIVF is 0% below the sector median of 33.3×
GAUDIUMIVF33.3×
Sector median33.3×
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 14.42 | 26.92 | 17.76 | 31.73 | 24.51 | 30.35 | 19.38 | 37.41 | |
| YoY Sales growth | +69.97% | +12.74% | +9.12% | +17.90% | |||||
| Expenses | 8.76 | 18.20 | 12.61 | 17.96 | 17.95 | 18.18 | 16.95 | 23.94 | |
| Operating Profit | 5.66 | 8.72 | 5.15 | 13.77 | 6.56 | 12.17 | 2.43 | 13.47 | |
| OPM % | 39.25% | 32.39% | 29.00% | 43.40% | 26.76% | 40.10% | 12.54% | 36.01% | |
| Other Income | 0.00 | 0.23 | 0.00 | 0.15 | 0.10 | 0.18 | 1.12 | 1.09 | |
| Interest | 0.39 | 0.43 | 0.50 | 0.51 | 1.20 | 1.29 | 0.38 | 0.52 | |
| Depreciation | 0.58 | 0.36 | 0.61 | 0.61 | 0.49 | 0.64 | 0.72 | 1.41 | |
| Profit before tax | 4.69 | 8.16 | 4.04 | 12.80 | 4.97 | 10.42 | 2.45 | 12.63 | |
| Tax % | 27.72% | 20.96% | 24.01% | 26.64% | 26.96% | 19.77% | 27.76% | 25.42% | |
| Net Profit | 3.40 | 6.46 | 3.07 | 9.38 | 3.63 | 8.36 | 1.78 | 9.41 | |
| EPS in Rs | 0.55 | 1.05 | 0.50 | 1.53 | 0.59 | 1.15 | 0.24 | 1.29 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.00% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26◦ |
| Earnings day | −2.00% |
| +1 day | −3.95% |
| +5 days | −11.40% |
| +15 days | −7.40% |
| +30 days | −10.77% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202671.29%Promoter
Promoters71.29%
FIIs1.19%1.82
DIIs2.22%
Public25.28%1.81
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,993.00 | 55.24 | 33,452 | 0.70% | 194 | +28.75% | 874 | +19.61% | 28.00% |
| Vijaya Diagnost. | ₹1,410.10 | 71.31 | 14,524 | 0.14% | 59 | +37.41% | 255 | +26.71% | 20.53% |
| Metropolis Healt | ₹564.20 | 50.73 | 11,709 | 0.35% | 75 | +43.04% | 497 | +15.76% | 17.81% |
| Thyrocare Tech. | ₹498.25 | 45.32 | 7,940 | 1.87% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹651.05 | 51.10 | 6,547 | 0.00% | 34 | +454.07% | 303 | +23.47% | 15.34% |
| Suraksha Diagno. | ₹341.70 | 42.55 | 1,780 | 0.15% | 15 | +66.96% | 99 | +25.84% | 17.29% |
| Krsnaa Diagnost. | ₹528.75 | 16.98 | 1,715 | 0.38% | 25 | +8.95% | 240 | +31.17% | 12.71% |
| Gaudium IVF | ₹106.14 | 33.33 | 773 | 0.00% | 9 | +0.32% | 37 | +17.90% | 29.54% |
| Median: 17 Co. | ₹341.70 | 33.33 | 869 | 0.00% | 12 | +12.09% | 90 | +19.61% | 20.53% |
Filings
Annual reports2
Concall transcripts8
Announcements5
Announcement under Regulation 30 (LODR)-Investor Presentation 15 Nov - Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov - Newspaper Publication of the unaudited and consolidated Financial Results for the quarter and half year ended September 30, 2026Rectification Of Inadvertent Typographical Error In The Unaudited Consolidated Financial Results Submitted As Part Of The Outcome Of The Board Meeting Held On November 12, 2026 13 Nov - Resubmitted Q2 FY27 results after correcting paid-up equity share capital; no change in profit or EPS.Announcement under Regulation 30 (LODR)-Monitoring Agency Report 12 Nov - Monitoring Agency Report for quarter ended September 30, 2026 shows nil deviation in IPO proceeds utilisation.Revised Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive Information Pursuant To Regulation 8(2) Of SEBI (PIT) Regulations, 2015. 12 Nov - Board approved Q2 FY2026 results, appointed Dr. Ravish Manchanda, and proposed IPO object variation for 19 IVF centres.



